Search the Newsreel

Lawsuit investigation launched over Gildan Activewear's alleged misleading growth claims causing stock drop

The Rosen Law Firm has initiated an investigation into a potential class action lawsuit against Gildan Activewear Inc. The investigation follows allegations that Gildan issued misleading information about its organic growth and sales, leading to a significant stock price drop after a short seller …

Press Release: Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Gilead Sciences announced its plans to release second-quarter 2026 financial results on Tuesday, August 4, 2026. The company will host a webcast and conference call to discuss these results later that day. Interested parties can access the webcast and accompanying slides on the company's …

ETFs Investing in Gilead Sciences, Inc. Stocks

This article lists various ETFs that include Gilead Sciences, Inc. (GILD0) stocks in their portfolios. The ETFs are sorted by market value and provide details such as weight, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and 3-year NAV total …

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

FOSTER CITY, Calif., July 21, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will …

Gilead and Merck report weekly HIV trial results

Gilead Sciences (NASDAQ:GILD) and Merck (NYSE:MRK) have announced successful 48-week results for their once-weekly oral HIV regimen in two Phase 3 trials, ISLEND-1 and ISLEND-2. The trials showed that the treatment maintained viral suppression with a low percentage of patients above the viral-load threshold, …

Debt to equity ratio of Gilead Sciences, Inc. – BCS:GILD0

This article focuses on the debt to equity ratio of Gilead Sciences, Inc. (BCS:GILD0). While the information primarily consists of navigation and boilerplate text from a financial platform, it highlights the availability of financial data for the company on the Santiago Stock Exchange via …

Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill

Gilead Sciences and Merck & Co. have announced positive Phase 3 trial results for their investigational once-weekly oral HIV regimen, ISL/LEN. The treatment demonstrated non-inferior efficacy to daily antiretroviral therapy and showed high patient satisfaction due to reduced treatment burden. These findings are expected …

Preferred dividends of Gilead Sciences, Inc. – BCS:GILDCL1

This page provides information on the preferred dividends of Gilead Sciences, Inc. under the ticker BCS:GILDCL1 on the Santiago Stock Exchange. It indicates that the market was closed with no trades recorded regarding these dividends.

Nasdaq 100 Movers: TRI, SNDK

In early trading on Tuesday, shares of SanDisk topped the list of the day's best performing components of the Nasdaq 100 index, trading up 9.7%. Year to date, SanDisk registers a 542.7% gain. And the worst performing Nasdaq 100 component thus far on the …

Gilead, Merck’s phase 3 data back first weekly HIV pill

New phase 3 data from two Islend clinical trials indicate that the experimental once-weekly, single-tablet combination of Gilead’s lenacapavir and Merck’s islatravir (ISL/LEN) effectively maintains HIV viral suppression, matching daily treatments like Gilead’s Biktarvy. If approved, ISL/LEN would be the first complete weekly oral …

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

– Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP – – Detailed Phase 3 Results from the ISLEND-1 and ISLEND-2 Trials Highlight the Potential of Weekly HIV …

Press Release: Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

Gilead Sciences has announced the completion of its strategic acquisition of Tubulis, a German-based biotechnology company. This acquisition is set to enhance Gilead's oncology portfolio, particularly in the area of antibody-drug conjugates (ADCs) for cancer treatment. The integration of Tubulis's innovative ADC platform and …

Gilead Sciences' Quarterly Earnings Preview: What You Need to Know

Gilead sign is seen during the fifth China International Import Expo By Eagle Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $166.7 billion by …

Did Accounting Probes and Channel Stuffing Claims Just Shift Gildan Activewear’s (TSX:GIL) Investment Narrative?

Gildan Activewear (TSX:GIL) is facing an expanded investigation by The Law Offices of Frank R. Cruz over alleged federal securities law violations, including claims of revenue inflation through channel stuffing and off-balance sheet receivables transfers, as reported by Jehoshaphat Research. These accounting allegations are …

Gildan Activewear (TSE:GIL) Stock Price Passes Above Fifty Day Moving Average - What's Next?

Lobbying Update: $1,590,000 of GILEAD SCIENCES INC lobbying was just disclosed

A recent Lobbying Disclosure Act filing for Q2 2026 reveals that GILEAD SCIENCES INC lobbied with $1,590,000 on issues including pharmaceuticals, intellectual property, drug pricing, and tax policy. The article also provides GILD stock trading activity by members of Congress and company insiders, as …

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today

Gilead Sciences (NASDAQ: GILD) has outperformed the market over the last 20 years with an average annual return of 11.43%. An initial investment of $100 in GILD twenty years ago would now be worth $854.46 due to compounded returns. The article highlights the significant …

Gildan Activewear (NYSE:GIL) Given a $80.00 Price Target by Stifel Nicolaus Analysts

Stifel Nicolaus analysts have set an $80.00 price target for Gildan Activewear (NYSE:GIL), reiterating a "buy" rating and implying a 44% upside. This follows Gildan's recent quarterly earnings beat, where the company reported $0.43 EPS, surpassing estimates, and maintained its FY2026 EPS guidance. The …

Gildan Activewear Inc. stock rises Monday, outperforms market

Gildan Activewear Inc. (GIL) saw its stock rise by 1.31% to C$76.73 on Monday, outperforming the broader Canadian market. This occurred during a session where the S&P/TSX Composite Index fell by 0.86%. Despite the daily gain, the company's stock closed 23.6% below its 52-week …

S&P 500 Futures Rise in Premarket Trading; First Citizens Bcshs A, Ermenegildo Zegna Lag

S&P 500 futures are rising in premarket trading, indicating a positive start for the U.S. stock markets. Among individual stocks, Hut 8 Corp. (HUT) and IREN Ltd. (IREN) are showing significant gains, up 13.9% and 8.6% respectively. However, First Citizens Bcshs A and Ermenegildo …

Mediolanum International Funds Ltd Trims Position in Gildan Activewear, Inc. $GIL

Mediolanum International Funds Ltd reduced its holdings in Gildan Activewear, Inc. (NYSE:GIL) by 9.8% in the first quarter, selling 30,518 shares and leaving it with 279,549 shares valued at $15.0 million. Despite this trimming, analysts maintain a "Moderate Buy" consensus rating for Gildan with …

Wall Street Zen Downgrades Ermenegildo Zegna (NYSE:ZGN) to Hold

Wall Street Zen downgraded Ermenegildo Zegna (NYSE:ZGN) from a “buy” to a “hold” rating. This decision contributes to a mixed analyst sentiment for the luxury fashion company, which currently holds a consensus rating of “Moderate Buy” and an average price target of $13.01. Several …

GIL6184631 Bond Risk Profile

This page provides a risk profile for the Gildan Activewear Inc. 4.7% 07-OCT-2030 bond, identified as GIL6184631 FINRA. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help users evaluate bond reliability. The platform also offers …

Gilead Stock Tops 3 GARP Picks Trading On More Measured Valuations

This article highlights three Growth at a Reasonable Price (GARP) stocks—Belden (BDC), Daktronics (DAKT), and Gilead Sciences (GILD)—that offer solid fundamentals and appear reasonably valued compared to the current AI-driven market trends. It discusses their revenue streams, market caps, and potential risks, suggesting they …

GIL6184631 Bond Profile — Key Metrics

This article provides key metrics for the GIL6184631 bond issued by Gildan Activewear Inc. It details the bond's coupon rate, maturity date, issue date, outstanding amount, and face value. It also includes a brief company description for Gildan Activewear.

Financiere des Professionnels Fonds d investissement inc. Makes New Investment in Gildan Activewear, Inc. $GIL

Financiere des Professionnels Fonds d investissement inc. has made a new investment in Gildan Activewear, acquiring 23,300 shares valued at approximately $1.3 million during the first quarter. Wall Street analysts maintain a "Moderate Buy" consensus for Gildan, with an average price target of $78.21. …

Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest close session, Gilead Sciences (GILD) was down 1.48% at $134.28. This change lagged the S&P 500's daily loss of 1.01%. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, lost 1.4%. Shares of the HIV and hepatitis C drugmaker …

With Up To Date campaign, Gilead brings HIV prevention into the dating conversation

Gilead Sciences has launched its "Up To Date" campaign, featuring comedians Nicole Byer and Devon Walker, to normalize conversations around HIV prevention, testing, and PrEP, particularly targeting Black women. The campaign uses humor and culturally relevant media placements like streaming services, social media, and …

Gildan Activewear Inc. (GIL) Shares Tumble 18% Amid Activist Forensic Report Challenging Company's Business Practices And Potentially Improper Revenue Recognition -- HBSS

Gildan Activewear Inc. (GIL) shares plummeted 18% after Jehoshaphat Research published a forensic report alleging improper channel stuffing and revenue recognition practices. This report, based on interviews with former employees and customers, wiped out $2.15 billion from Gildan's market capitalization. Hagens Berman has launched …

ETFs Investing in Gildan Activewear Inc. Stocks

This article lists Exchange Traded Funds (ETFs) that hold stocks of Gildan Activewear Inc. It provides a table detailing various ETFs, including their market value, weight of Gildan Activewear Inc. stock, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, relative …

Is Gilead Sciences (GILD) Fully Valued Following Mixed Earnings And A Full Year EPS Miss?

Gilead Sciences (GILD) reported mixed Q2 earnings with revenue up 4.4% to $6.96 billion but missed full-year EPS estimates. While one valuation narrative suggests Gilead is 6.2% overvalued at $136.30 with a fair value of $128.38, another Discounted Cash Flow (DCF) model indicates it …

Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock on July 15, 2026, for approximately $390,000, under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Dickinson still directly holds 168,646 shares. The sale was executed at an average …

Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overvalued -- GF Score: 69/100

Gilead Sciences Inc (GILD) saw its stock price rise by 3.5% on July 16, 2026, reaching $136.30. Despite this gain, GuruFocus's GF Value™ estimates the stock to be significantly overvalued at $96.17, implying a 41.7% premium. The GF Score™ of 69/100 suggests above-average performance …

Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan

Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences (NASDAQ: GILD), reported an open-market sale of 3,000 shares of common stock on July 15, 2026, at an average price of $129.9192 per share. This sale was conducted under a Rule 10b5-1 trading …

Gilead Sciences chief comm & corp aff officer sells $389,757 in stock

Johanna Mercier, Chief Communications & Corporate Affairs Officer at Gilead Sciences (NASDAQ:GILD), sold 3,000 shares of company stock for approximately $389,757 on July 15, 2026, as part of a pre-arranged trading plan. Despite the sale, the stock is considered potentially undervalued according to InvestingPro …

Ermenegildo Zegna (NYSE:ZGN) Shares Up 6.6% - Should You Buy?

Ermenegildo Zegna (NYSE:ZGN) shares increased by 6.6% on Thursday, reaching $14.33 with higher-than-average trading volume, indicating renewed investor interest. Wall Street analysts have a "Moderate Buy" consensus rating with an average target price of $13.01, though some recent insider selling by the director and …